7 Pharmaceuticals Stocks to Sell Now

Advertisement

This week, the ratings of 7 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Shire PLC Sponsored ADR (SHPG) declines this week from a C to a D. Shire PLC Sponsored ADR a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SHPG stock.

This week, Mylan N.V.’s (MYL) rating worsens to a D from the company’s C rating a week ago. Mylan N.V. is a global generic and specialty pharmaceuticals company. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MYL stock.

GlaxoSmithKline plc Sponsored ADR (GSK) is having a tough week. The company’s rating falls from a C to a D. GlaxoSmithKline plc Sponsored ADR is a research-based pharmaceutical company. For more information, get Portfolio Grader’s complete analysis of GSK stock.

This week, POZEN Inc. (POZN) drops from a C to a D rating. POZEN Inc. is a pharmaceutical company that develops therapeutics for diseases with unmet medical needs. The company also gets F’s in sales growth, earnings growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of POZN stock.

Slipping from a C to a D rating, XenoPort, Inc. (XNPT) takes a hit this week. XenoPort, Inc. is a biopharmaceutical company that focuses on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of XNPT stock.

Auris Medical Holding AG’s (EARS) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EARS stock.

This is a rough week for Pernix Therapeutics Holdings, Inc. (PTX). The company’s rating falls to F from the previous week’s D. Pernix Therapeutics Holdings, Inc. manufactures pharmaceuticals. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of PTX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/10/7-pharmaceuticals-stocks-to-sell-now/.

©2024 InvestorPlace Media, LLC